Effect of a thromboxane synthetase inhibitor, ozagrel hydrochloride, on peak expiratory flow in stable asthmatics treated with beclomethasone diproprionate

Allergology International

Volumn 46, Issue 1, 1997, Pages 25-28

  Fujimura, Masaki ^a   Nakatsumi, Yasuto ^a   Matsuda, Tamotsu ^a   Nishi, Kouichi ^b   Kasahara, Kazuo ^c   Ogawa, Haruhiko ^d  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Kanazawa City Hospital   (Japan)

^d TOYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

asthma; ozagrel hydrochloride; peak expiratory flow; steroid inhalation therapy; thromboxane synthetase inhibitor

Indexed keywords

EID: 85010086212     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.46.25     Document Type: Article

References (5)

1. Scheffer, A.L. International consensus report on diagnosis and treatment of asthma. Clin. Exp. Allergy 1992; 22: 39–52.
2. Flower, R.J. Lipocortin and the mechanism of action of the glucocorticoids. Br. J. Pharmacol. 1988; 94: 987–1015.
3. Chung, K.F., Wiggins, J., Collins, J. Corticosteroids. In: Weiss EB, Stein M (eds). Bronchial Asthma: Mechanisms and Therapeutics, 3rd edn. Boston/Toronto/London: Little, Brown and Company, 1993; 800–817.
4. Kabe, J. A double-blind placebo-controlled study of OKY-046 for the treatment of chronic asthma. Jpn. J. Med. 1989; 28: 552–555.
5. Tamura, G. The role of leukotrienes in asthma. In: Kimura I, Fujimura M (eds). The Significant Role of Lipid Mediators in Asthma Pathophysiology. Tokyo: Nippon Akcel Springer, 1993; 25–32 (in Japanese).